254 related articles for article (PubMed ID: 32293356)
1. Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Kang HN; Kim JH; Park AY; Choi JW; Lim SM; Kim J; Shin EJ; Hong MH; Pyo KH; Yun MR; Kim DH; Lee H; Yoon SO; Kim DH; Park YM; Byeon HK; Jung I; Paik S; Koh YW; Cho BC; Kim HR
BMC Cancer; 2020 Apr; 20(1):316. PubMed ID: 32293356
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV
Brand TM; Hartmann S; Bhola NE; Peyser ND; Li H; Zeng Y; Isaacson Wechsler E; Ranall MV; Bandyopadhyay S; Duvvuri U; LaVallee TM; Jordan RCK; Johnson DE; Grandis JR
Clin Cancer Res; 2017 Jun; 23(12):3072-3083. PubMed ID: 27986750
[No Abstract] [Full Text] [Related]
3. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
[TBL] [Abstract][Full Text] [Related]
4. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
[TBL] [Abstract][Full Text] [Related]
7. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
Facompre ND; Rajagopalan P; Sahu V; Pearson AT; Montone KT; James CD; Gleber-Netto FO; Weinstein GS; Jalaly J; Lin A; Rustgi AK; Nakagawa H; Califano JA; Pickering CR; White EA; Windle BE; Morgan IM; Cohen RB; Gimotty PA; Basu D
Int J Cancer; 2020 Dec; 147(11):3236-3249. PubMed ID: 32478869
[TBL] [Abstract][Full Text] [Related]
8. Barriers to generating PDX models of HPV-related head and neck cancer.
Facompre ND; Sahu V; Montone KT; Harmeyer KM; Nakagawa H; Rustgi AK; Weinstein GS; Gimotty PA; Basu D
Laryngoscope; 2017 Dec; 127(12):2777-2783. PubMed ID: 28561270
[TBL] [Abstract][Full Text] [Related]
9. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
[TBL] [Abstract][Full Text] [Related]
10. Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
Swick AD; Stein AP; McCulloch TM; Hartig GK; Ong IM; Sampene E; Prabakaran PJ; Liu CZ; Kimple RJ
Oral Oncol; 2017 Jan; 64():65-72. PubMed ID: 28024726
[TBL] [Abstract][Full Text] [Related]
11. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Keysar SB; Astling DP; Anderson RT; Vogler BW; Bowles DW; Morton JJ; Paylor JJ; Glogowska MJ; Le PN; Eagles-Soukup JR; Kako SL; Takimoto SM; Sehrt DB; Umpierrez A; Pittman MA; Macfadden SM; Helber RM; Peterson S; Hausman DF; Said S; Leem TH; Goddard JA; Arcaroli JJ; Messersmith WA; Robinson WA; Hirsch FR; Varella-Garcia M; Raben D; Wang XJ; Song JI; Tan AC; Jimeno A
Mol Oncol; 2013 Aug; 7(4):776-90. PubMed ID: 23607916
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.
Lee RH; Roy R; Li H; Hechmer A; Zhu TR; Izgutdina A; Olshen AB; Johnson DE; Grandis JR
PLoS One; 2023; 18(3):e0282177. PubMed ID: 36857322
[TBL] [Abstract][Full Text] [Related]
15. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
16. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
[No Abstract] [Full Text] [Related]
17. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Bhatia S; Griego A; Lennon S; Oweida A; Sharma J; Rohmer C; Uyanga N; Bukkapatnam S; Van Court B; Raben D; Young C; Heasley L; Karam SD
Mol Cancer Ther; 2018 Sep; 17(9):2049-2059. PubMed ID: 29970482
[TBL] [Abstract][Full Text] [Related]
18.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
19. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
20. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
